• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Prescribing of SGLT2 inhibitors in primary care: a qualitative study of General Practitioners and Endocrinologists
In 2015, the EMPA-REG OUTCOME trial reported that treatment with the sodium-glucose cotransporter 2 (SGLT2) inhibitor, empagliflozin, significantly reduced the risk of the primary composite outcome – death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke in patients with type 2 diabetes at high cardiovascular risk [1]. Since that landmark trial, many other large randomised controlled trials (RCTs) have confirmed the cardiovascular (particularly with respect to he art failure) and renal benefits of this drug class [2–7].
Source: Diabetes Research and Clinical Practice - September 2, 2021 Category: Endocrinology Authors: Tamara Y. Milder, Sophie L. Stocker, Melissa Baysari, Richard O. Day, Jerry R. Greenfield Source Type: research

Invited review. Series: Implications of the recent CVOTs in type 2 diabetes
Large cardiovascular outcome trials (CVOTs) have lent support to a cardiovascular protection with the use of SGLT2-inhibitors (SGLT2is) and GLP1-Receptor Agonists (GLP1-RAs) in subjects with type 2 diabetes. These two classes of novel glucose lowering agents have been shown to have a similar effect on the risk reduction of Major Adverse Cardiovascular Events (MACE: nonfatal myocardial infarction, nonfatal stroke, cardiovascular mortality). Nonetheless, they may not be simply interchangeable. Rather, careful evaluation of all the results of CVOTs allows identification of different effects that may allow profiling of the ide...
Source: Diabetes Research and Clinical Practice - March 16, 2020 Category: Endocrinology Authors: Angela Dardano, Roberto Miccoli, Cristina Bianchi, Giuseppe Daniele, Stefano Del Prato Source Type: research

Meta-analyses of the effects of Dpp-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure
To assess the effects DPP- 4i; SGLT2-i& GLP1-RA on CV death, MI, stroke and hHF . This is probably the first meta-analysis to assess the effects of these drugs on MI and stroke in totality, including non-fatal& fatal MI and stroke.
Source: Diabetes Research and Clinical Practice - February 19, 2019 Category: Endocrinology Authors: Binayak Sinha, Samit Ghosal Source Type: research

SGLT2 inhibitors with cardiovascular benefits: transforming clinical care in Type2 diabetes mellitus
Persons with type2 diabetes mellitus (T2DM) are at higher risk than persons without diabetes of developing atherosclerotic vascular diseases and events including myocardial infarction and stroke, as well as complications such as chronic kidney disease [1,2]. Optimal management of their diabetes and its comorbidities is required to address the increased risk of cardiovascular and related diseases [3]. Certain sodium –glucose co-transporter 2 (SGLT2) inhibitors have recently been shown to improve cardiovascular outcomes in high cardiovascular-risk individuals with T2DM, with empagliflozin being the first to demonstrate a r...
Source: Diabetes Research and Clinical Practice - November 28, 2017 Category: Endocrinology Authors: Michael d'Emden, John Amerena, Gary Deed, Carol Pollock, Mark E. Cooper Tags: Review Source Type: research

SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus
Persons with type 2 diabetes mellitus (T2DM) are at higher risk than persons without diabetes of developing atherosclerotic vascular diseases and events including myocardial infarction and stroke, as well as complications such as chronic kidney disease [1,2]. Optimal management of their diabetes and its comorbidities is required to address the increased risk of cardiovascular and related diseases [3]. Certain sodium –glucose co-transporter 2 (SGLT2) inhibitors have recently been shown to improve cardiovascular outcomes in high cardiovascular-risk individuals with T2DM, with empagliflozin being the first to demonstrate a ...
Source: Diabetes Research and Clinical Practice - November 28, 2017 Category: Endocrinology Authors: Michael d'Emden, John Amerena, Gary Deed, Carol Pollock, Mark E. Cooper Tags: Review Source Type: research